Abstract 4CPS-198 Table 1
DEMOGRAPHICSn (%)TREATMENT(%)
Age69.6 (46–85)DAL administered following hospitalisation77.3%
Male59.1%Previous antimicrobials for actual episode100%
DIAGNOSES Switching to DAL
Osteoarticular infections45.5%Discharge64.7%
Resistant pathogens22.7%
Drug-induced toxicity13.6%
Bloodstream infections22.7%Difficult vascular access9.1%
Acute bacterial skin and skin structure infections13.6%Drug-drug interactions4.5%
Endocarditis13.6% DAL initial – weekly doses
1,000–500 mg63.3%
MICROBIOLOGY750–350 mg4.5%
Samples available90.9%1,500–1,500 mg4.5%
S. aureus54.5%1,500 – single dose27,3%
MRSA58.3% DAL number of doses:
CNS27.3%236.4%
Methicillin-resistant CNS66.7%single31.8%
E. faecalis4.5%≥527.3%
E.faecium4.5% ADVERSE EVENTS
OUTCOMESInfusion site reaction4.5%
Success treatment95.2%Others0